Leprosy and the peripheral nervous system: Basic and clinical aspects
Corresponding Author
Winnie W. Ooi MD, DMD, MPH
Department of Infectious Disease, Lahey Clinic, 41 Mall Road, Burlington, Massachusetts 01805, USA
Department of Infectious Disease, Lahey Clinic, 41 Mall Road, Burlington, Massachusetts 01805, USASearch for more papers by this authorJayashri Srinivasan MB, BS, PhD
Department of Neurology, Lahey Clinic, Burlington, Massachusetts, USA
Search for more papers by this authorCorresponding Author
Winnie W. Ooi MD, DMD, MPH
Department of Infectious Disease, Lahey Clinic, 41 Mall Road, Burlington, Massachusetts 01805, USA
Department of Infectious Disease, Lahey Clinic, 41 Mall Road, Burlington, Massachusetts 01805, USASearch for more papers by this authorJayashri Srinivasan MB, BS, PhD
Department of Neurology, Lahey Clinic, Burlington, Massachusetts, USA
Search for more papers by this authorAbstract
Leprosy is one of the most common causes of nontraumatic peripheral neuropathy in the developing world. The causative agent, Mycobacterium leprae, has a predilection for Schwann cells, where the organism multiplies unimpeded by organism-specific host immunity, resulting in destruction of myelin, secondary inflammatory changes, and destruction of the nerve architecture. The cardinal diagnostic features of leprosy are anesthetic skin lesions, neuropathy, and positive skin smears for the bacilli. However, patients may rarely present without skin lesions in pure neuritic leprosy. Electrodiagnostic findings early in the disease reveal demyelinating features, such as slowing of conduction velocity and prolongation of latencies, but as the disease progresses secondary axonal damage commonly ensues. Electrodiagnostic studies are also useful to monitor for toxicity secondary to therapy, particularly thalidomide-associated neuropathy. Nerve biopsy of a sensory cutaneous nerve is sometimes essential to confirm a diagnosis of leprosy. Significant advances in understanding of the pathogenesis, mapping of the genome, and other advances in molecular biology may result in better preventive and therapeutic modalities, and the goal of eradicating leprosy as a global problem may yet be realized. Muscle Nerve 30: 393–409, 2004
REFERENCES
- 1 Abel L, Sanchez FO, Oberti J, Thuc NV, Hoa LV, Lap VD, Skamene E, Lagrange PH, Schurr E. Susceptibility to leprosy is linked to the human NRAMP1 gene. J Infect Dis 1998; 177: 133–145.
- 2 Alcais A, Sanchez FO, Thuc NV, Lap VD, Oberti J, Lagrange PH, Schurr E, Abel L. Granulomatous reaction to intradermal injection of lepromin (Mitsuda reaction) is linked to the human NRAMP1 gene in Vietnamese leprosy sibships. J Infect Dis 2000; 181: 302–328.
- 3 Altman DJ, Amato AA. Lepromatous neuropathy. J Clin Neuromuscul Dis 1999; 1; 68–73.
- 4Anonymous. Leprosy Resolution WHA 44.9, Forty-fourth World Health Assembly, 13 May 1991. Global strategy for the elimination of leprosy as a public health problem.
- 5Anonymous. Leprosy: global situation. WHO Wkly Epidemiol Rec 2002; 1: 1–8.
- 6Anonymous. WHO Expert Committee on Leprosy, 7th report. Technical report series 874. Geneva: WHO; 1998.
- 7 Bastuji-Garin S, Ochonisky S, Bouche P, Gherardi RK, Duguet C, Djerradine Z, Poli F, Revuz J. Thalidomide Neuropathy Study Group. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. J Invest Dermatol 2002; 119: 1020–1026.
- 8 Ben Hamida M, Letaief F, Ben Hamida C. Histomorphometric study of the superficial peroneal nerve in leprosy. Acta Leprol 1987; 5: 101–114.
- 9 Blackwell JM. Modern genetics and leprosy susceptibility. Lepr Rev 2001; 72: 352–356.
- 10 Blake LA, West BC, Lary CH, Todd JR. Environmental nonhuman sources of leprosy. Rev Infect Dis 1987; 9: 562–577.
- 11 Bleharski JR, Li H, Meinken C, Graeber TG, Ochoa MT, Yamamura M, Burdick A, Sarno EN, Wagner M, Rollinghoff M, Rea TH, Colonna M, Stenger S, Bloom BR, Eisenberg D, Modlin RL. Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science 2003; 301: 1527–1530.
- 12 Blum L, Flageul B, Sow S, Launois P, Vignon-Pennamen MD, Coll A, Millan J. Leprosy reversal reaction in HIV-positive patients. Int J Lepr Other Mycobact Dis 1993; 61: 214–217.
- 13 Boddingius, J. The occurrence of Mycobacterium leprae within axons of peripheral nerves. Acta Neuropathol 1974; 27: 257–270.
- 14 Britton WJ, Martin E, Kamath AT, Neupane KD, Roche PW. Immunoprophylaxis against Mycobacterium leprae infection with subunit vaccines. Lepr Rev 2000; 71(Suppl): S176–181.
- 15 Brophy PJ. Subversion of Schwann cells and the leper's bell. Science 2002; 296: 862–863.
- 16
Brown TR,
Kovindha A,
Wathanadilokkol U,
Smith T,
Kraft GH.
Abnormalities of the sympathetic skin response in lepromatous leprosy.
Muscle Nerve
1996;
19:
1357–1358.
10.1002/(SICI)1097-4598(199610)19:10<1357::AID-MUS19>3.0.CO;2-R CAS PubMed Web of Science® Google Scholar
- 17 Brown TR, Kovindha A, Wathanadilokkol U, Piefer A, Smith T, Kraft GH. Leprosy neuropathy: correlation of clinical and electrophysiological tests. Indian J Lepr 1996; 68: 1–14.
- 18 Buhrer-Sekula S, Cunha MG, Foss NT, Oskam L, Faber WR, Klatser PR. Dipstick assay to identify leprosy patients who have an increased risk of relapse. Trop Med Int Health 2001; 6: 317–323
- 19 Bwire R, Kawuma HJ. Type 1 reactions in leprosy, neuritis and steroid therapy: the impact of the human immunodeficiency virus. Trans R Soc Trop Med Hyg 1994; 88: 315–316.
- 20 Cambau E, Bonnafous P, Perani E, et al. Molecular detection of rifampin and ofloxacin resistance for patients who experienced relapse of multibacillary leprosy. Clin Infect Dis 2002; 34: 39–45.
- 21 Cellona RV, Walsh GP, Fajardo TT Jr, Abalos RM, dela Cruz EC, Guido-Villahermosa L, Felicio-Balagon MV, Steenbergen GJ, Douglas JT. Cross-sectional assessment of ELISA reactivity in leprosy patients, contacts, and normal population using the semisynthetic antigen natural disaccharide octyl bovine serum albumin (ND-O-BSA) in Cebu, The Philippines. Int J Lepr Other Mycobact Dis 1993; 61: 192–198.
- 22 Celik O, Yalcin S, Gok U, Yavrucuoglu E, Ozturk A, Akyol A. Auditory brain stem evoked potentials in patients with leprosy. Int J Lepr Other Mycobact Dis 1997; 65: 166–169.
- 23 Chad DA, Hedley-Whyte ET. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2004. A 49-year-old woman with asymmetric painful neuropathy. N Engl J Med 2004; 350: 166–176.
- 24 Chakrabarty AN, Dastidar SG. Is soil an alternative source of leprosy infection? Acta Leprol 2001; 12: 79–84.
- 25 Chandi SM, Chacko CJG. An ultrastructural study of the response of traumatized rabbit tibial nerve to epineurial infection with M. leprae. Int J Lepr Other Mycobact Dis 1986; 54: 79–83.
- 26 Chandi SM, Chacko CJ. An ultrastructural study of dermal nerves in early human leprosy. Int J Lepr Other Mycobact Dis 1987; 55: 515–520.
- 27 Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872–1875.
- 28 Chauhan SL, Girdhar A, Mishra B, Malaviya GN, Venkatesan K, Girdhar BK. Calcification of peripheral nerves in leprosy. Acta Leprol 1996; 10: 51–56.
- 29 Chimelli L, Freitas M, Nascimento O. Value of nerve biopsy in the diagnosis and follow-up of leprosy: the role of vascular lesions and usefulness of nerve studies in the detection of persistent bacilli. J Neurol 1997; 244: 318–323.
- 30 Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honore N, Garnier T, Churcher C, Harris D, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroix C, Maclean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Stevens K, Taylor K, Whitehead S, Woodward JR, Barrell BG. Massive gene decay in the leprosy bacillus. Nature 2001; 409: 1007–1011.
- 31 Cole ST, Supply P, Honore N. Repetitive sequences in Mycobacterium leprae and their impact on genome plasticity. Lepr Rev 2001; 72: 449–461.
- 32 Consigny S, Bentoucha A, Bonnafous P, Grosset J, Ji B. Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice. Antimicrob Agents Chemother 2000; 44: 2919–2921.
- 33 Croft RP, Nicholls PG, Richardus JH, et al. The treatment of acute nerve function impairment in leprosy: results from a prospective cohort study in Bangladesh. Lepr Rev 2000; 71: 138–145.
- 34 Curtiss R III, Blower S, Cooper K, Russell D, Silverstein S, Young L. Leprosy research in the post-genome era. Lepr Rev 2001; 72: 8–22.
- 35 Dastur DK, Antia NH, Divekar SC. The facial nerve in leprosy. 2. Pathology, pathogenesis, electromyography and clinical correlations. Int J Lepr Other Mycobact Dis 1966; 34: 118–138.
- 36 De Carsalade GY, Achirafi A, Flageul B. Pentoxifylline in the treatment of erythema nodosum leprosum. J Dermatol 2003; 30: 64–68.
- 37 de Vries RRP, Ottenhoff THM. Immunogenetics of leprosy. In: RC Hastings, editor. Leprosy, 2nd ed. Edinburgh: Churchill Livingstone; 1994. p 113–121.
- 38 Dhand UK, Kumar B, Dhand R, Chopra JS, Kaur S. Phrenic nerve conduction in leprosy. Int J Lepr Other Mycobact Dis 1988; 56: 389–393.
- 39 Durbeej M, Henry MD, Campbell KP. Dystroglycan in development and disease. Curr Opin Cell Biol 1998; 10: 594–601.
- 40 Dutta AK, Mandal SB, Jopling WH. Surface temperature of bald and hairy scalp in reference to leprosy affection. Ind J Dermatol 1983; 28: 1–5.
- 41 Eiglmeier K, Parkhill J, Honore N, Garnier T, Tekaia F, Telenti A, Klatser P, James KD, Thomson NR, Wheeler PR, Churcher C, Harris D, Mungall K, Barrell BG, Cole ST. The decaying genome of Mycobacterium leprae. Lepr Rev 2001; 72: 387–398.
- 42 Eiglmeier K, Simon S, Garnier T, Cole ST. The integrated genome map of Mycobacterium leprae. Lepr Rev 2001; 72: 462–469.
- 43 Fitness J, Tosh K, Hill AV. Genetics of susceptibility to leprosy. Genes Immunol 2002; 3: 441–453.
- 44 Fine PEM. BCG vaccination against tuberculosis and leprosy. Br Med Bull 1988; 44: 691–703.
- 45 Gebre S, Saunderson P, Messele T, Byass P. The effect of HIV status on the clinical picture of leprosy: a prospective study in Ethiopia. Lepr Rev 2000; 71: 338–343.
- 46 Ghorpade A. Inoculation (tattoo) leprosy: a report of 31 cases. J Eur Acad Dermatol Venereol 2002; 16: 494–499.
- 47 Gibbels E, Behse F, Klingmuller G, Henke-Lubke U, Haupt WF, Gollmer E. Sural nerve biopsy findings in leprosy: a qualitative and quantitative light and electron microscope study in 4 treated cases of the lepromatous spectrum. Clin Neuropathol 1988; 7: 120–130.
- 48 Girdhar BK, Girdhar A, Kumar, A. Relapses in multibacillary leprosy patients: effect of length of therapy. Lepr Rev 2000; 71: 144–153.
- 49 Godal T, Lofgren M, Negassi K. Immune response to M. leprae of healthy leprosy contacts. Int J Lepr Other Mycobact Dis 1972; 40: 243–250.
- 50 Godal T, Negassi K. Subclinical infection in leprosy. Br Med J 1973; 15: 557–559.
- 51 Grosset J, Guelpa-Lauras CC, Millan J, Bodian M, Perani E. Resistance of Mycobacterium leprae to dapsone and rifampicin: apropos of a survey carried out in the Cape Verde region (Senegal). Med Trop (Mars) 1987; 47: 171–175.
- 52 Grosset JH, Guelpa-Lauras CC, Bobin P, Brucker G, Cartel JL, Constant-Desportes M, Flageul B, Frederic M, Guillaume JC, Millan J. Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin. Int J Lepr Other Mycobact Dis 1989; 57: 607–614.
- 53 Gupta BK, Kochar DK. Study of nerve conduction velocity, somatosensory-evoked potential and late responses (H-reflex and F-wave) of posterior tibial nerve in leprosy. Int J Lepr Other Mycobact Dis 1994; 62: 586–593.
- 54 Gutmann L, Martin JD, Welton W. Dapsone motor neuropathy—an axonal disease. Neurology 1976; 26: 514–516.
- 55 Hackett ER, Shipley DE, Livengood R. Motor nerve conduction velocity studies of the ulnar nerve in patients with leprosy. Int J Lepr Other Mycobact Dis 1968; 36: 282–287.
- 56 Haimanot RT, Mshana RN, McDougall AC, Andersen JG. Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy. Int J Lepr Other Mycobact Dis 1984; 52: 163–170.
- 57 Hansen AG. Spedalskhedens aarsager. Norsk Mag Leagavid 1874; 4: 76–79.
- 58 Hastings RC, Trautman JR, Enna CD, Jacobson RR. Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum. Clin Pharmacol Ther 1970; 11: 481–487.
- 59 Hatagima A, Opromolla DV, Ura S, Feitosa MF, Beiguelman B, Krieger H. No evidence of linkage between Mitsuda reaction and the NRAMP1 locus. Int J Lepr Other Mycobact Dis 2001; 69: 99–103.
- 60 Hirata T, Harada N. Electron microscopic observations of the relationship between peripheral nerve tissue proper and an endoneurial capillary in a dermal lesion of relapsed lepromatous patient. Int J Lepr Other Mycobact Dis 1994; 62: 89–98.
- 61 Hunter SW, Fujiwara T, Brennan PJ. Structure and antigenicity of the major specific glycolipid antigen of Mycobacterium leprae. J Biol Chem 1982; 257: 15072–15078.
- 62 Husain S, Mishra B, Prakash V, Malaviya GN. Results of surgical decompression of ulnar nerve in leprosy. Acta Leprol 1998; 11: 17–20.
- 63 Indira D, Kaur I, Sharma VK, Das A. Palmoplantar lesions in leprosy. Ind J Lepr 1999; 71: 167–172.
- 64 Jacob M, Mathai R. Diagnostic efficacy of cutaneous nerve biopsy in primary neuritic leprosy. Int J Lepr Other Mycobact Dis 1988; 56: 56–60.
- 65 Jain M, Singh N, Bhatia A, Arora VK. Histological assessment of dermal nerve damage occurring during multidrug therapy for leprosy. Int J Lepr 2000; 68: 167–171.
- 66 Jardim MR, Antunes SL, Santos AR, Nascimento OJ, Nery JA, Sales AM, Illarramendi X, Duppre N, Chimelli L, Sampaio EP, Sarno EP. Criteria for diagnosis of pure neural leprosy. J Neurol 2003; 250: 806–809.
- 67 Johnson PC. Peripheral nerve pathology. In: RL Davis, DM Robertson, editors. Textbook of neuropathology, 3rd ed. Baltimore: Williams & Wilkins; 1997. p 1233–1323.
- 68 Joshi B, Girdhar BK, Mohanty KK, Beuria MK, Girdhar A, Sengupta U. Immunological profile of treated lepromatous leprosy patients. Int J Lepr Other Mycobact Dis 2001; 69: 195–203.
- 69 Job CK. Pathology and pathogenesis of leprous neuritis; a preventable and treatable complication. Int J Lepr Other Mycobact Dis 2001; 69(Suppl): S10–S29.
- 70 Job CK. Pathology of peripheral nerve lesions in lepromatous leprosy—a light and electron microscopic study. Int J Lepr Other Mycobact Dis 1971; 39: 251–268.
- 71 Job CK, Desikan KV. Pathologic changes and their distribution in peripheral nerves in lepromatous leprosy. Int J Lepr Other Mycobact Dis 1968; 36: 257–270.
- 72 Job CK, Verghese R. Schwann cell changes in lepromatous leprosy–an electronmicroscope study. Ind J Med Res 1975; 63: 897–901.
- 73 Jopling WH, Morgan-Hughes JA. Pure neural tuberculoid leprosy. Br Med J 1965; 5465: 799–800.
- 74 Joyce MP, Scollard DM, Gillis TP, William DL. Latent leprosy presenting in two rheumatoid arthritis patients treated with infliximab (a tumor necrosis factor inhibitor). Am J Trop Med 2003; 69(Suppl): 561.
- 75 Kang TJ, Chae GT. Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients FEMS Immunol Med Microbiol 2001; 31: 53–58.
- 76 Kaplan G, Weinstein DE, Steinman RM, Levis WR, Elvers U, Patarroyo ME, Cohn ZA. An analysis of in vitro T cell responsiveness in lepromatous leprosy. J Exp Med 1985; 162: 917–929.
- 77 Kaur I, Dogra S, Kumar B. Combined 12-month WHO/MDT MB regimen and mycobacterium w vaccine in multibacillary leprosy: a follow-up of 136 patients. Int J Lepr Other Mycobact Dis 2002; 70: 174–181.
- 78 Khanolkar VR. Studies in the histology of early lesions of leprosy. Special reports series. New Delhi, India: Indian Council of Medical Research; 1951. 19 p.
- 79
Kim J,
Uyemura K,
Van Dyke MK,
Legaspi AJ,
Rea TH,
Shuai K,
Modlin RL.
A role for IL-12 receptor expression and signal transduction in host defense in leprosy. A role for IL-12 receptor expression and signal transduction in host defense in leprosy.
J Immunol
2001;
15:
779–786.
10.4049/jimmunol.167.2.779 Google Scholar
- 80 Kirchheimer WF, Storrs EE. Attempts to establish the armadillo (Dasypus novemcinctus Linn.) as a model for the study of leprosy. I. Report of lepromatoid leprosy in an experimentally infected armadillo. Int J Lepr Other Mycobact Dis 1971; 39: 693–702.
- 81 Krutzik SR, Ochoa MT, Sieling PA, Uematsu S, Ng YW, Legaspi A, Liu PT, Cole ST, Godowski PJ, Maeda Y, Sarno EN, Norgard MV, Brennan PJ, Akira S, Rea TH, Modlin RL. Activation and regulation of Toll-like receptors 2 and 1 in human leprosy. Nat Med 2003; 9: 525–532.
- 82 Lawn SD, Wood C, Lockwood DN. Borderline tuberculoid leprosy: an immune reconstitution phenomenon in a human immunodeficiency virus-infected person. Clin Infect Dis 2003; 36: e5–6.
- 83 Leonard G, Sangare A, Verdier M, Sassou-Guesseau E, Petit G, Milan J, M'Boup S, Rey JL, Dumas JL, Hugon J, et al. Prevalence of HIV infection among patients with leprosy in African countries and Yemen. J AIDS 1990; 3: 1109–1113.
- 84 Lewallen S. Prevention of blindness in leprosy: an overview of the relevant clinical and programme-planning issues. Ann Trop Med Parasitol 1997; 91: 341–348.
- 85 Libraty DH, Airan LE, Uyemura K, Jullien D, Spellberg B, Rea TH, Modlin RL. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy. Clin Invest 1997; 99: 336–341.
- 86 Lienhardt C, Kamate B, Jamet P, Tounkara A, Faye OC, Sow SO, Bobin P. Effect of HIV infection on leprosy: a three-year survey in Bamako, Mali. Int J Lepr Other Mycobact Dis 1996; 64: 383–391.
- 87 Lockwood DN. Steroids in leprosy type 1 (reversal) reactions: mechanisms of action and effectiveness. Lepr Rev 2000; 71(Suppl): S111–S114.
- 88 Lockwood DN, Colston MJ, Khanolkar-Young SR. The detection of Mycobacterium leprae protein and carbohydrate antigens in skin and nerve from leprosy patients with type 1 (reversal) reactions. Am J Trop Med Hyg 2002; 66: 409–415.
- 89 Lockwood DN, Sinha HH. Pregnancy and leprosy: a comprehensive literature review. Int J Lepr Other Mycobact Dis 1999; 67: 6–12.
- 90 Lucas S. Human immunodeficiency virus and leprosy. Lepr Rev 1993; 64: 97–103.
- 91 Mahajan VK, Sharma NL, Sharma RC, Sharma A. Pulse dexamethasone, oral steroids and azathioprine in the management of erythema nodosum leprosum. Lepr Rev 2003; 74: 171–174.
- 92 Malaviya MB. Sensory perception in leprosy—neurophysiological correlates. Int J Lepr 2003; 71: 119–123.
- 93 Mastro TD, Redd SC, Breiman RF. Imported leprosy in the United States, 1978 through 1988: an epidemic without secondary transmission. Am J Publ Health 1992; 82: 1127–1130.
- 94 Marques W Jr, Foss NT, Arruda AP, Barreira AA. Near-nerve potential in lepromatous leprosy. Muscle Nerve 2003; 28: 460–463.
- 95 McDougall AC. The nasal excretion of leprosy bacilli. Lepr Rev 1978; 49: 265–267.
- 96 McLeod JG, Hargrave JC, Walsh JC, Booth GC, Gye RS, Barron A. Nerve conduction studies in leprosy. Int J Lepr Other Mycobact Dis 1975; 43: 21–31.
- 97 Meisner SJ, Mucklow S, Warner G, Sow SO, Lienhardt C, Hill AV. Association of NRAMP1 polymorphism with leprosy type but not susceptibility to leprosy per se in West Africans. Am J Trop Med Hyg 2001; 65: 733–735.
- 98 Miko TL, Le Maitre C, Kinfu Y. Damage and regeneration of peripheral nerves in advanced treated leprosy. Lancet 1993; 28: 342: 521–525.
- 99 Modlin RL. Th1–Th2 paradigm: insights from leprosy. J Invest Dermatol 1994; 102: 828–832.
- 100 Modlin RL, Melancon-Kaplan J, Young S, Pirmez C, Kino H, Vonvit J, Rea TH, Bloom BR. Learning from lesions: pattern of tissue inflammation in leprosy. Proc Natl Acad Sci USA 1988; 85: 1213–1217.
- 101 Molloy FM, Floeter MK, Syed NA, Sandbrink F, Culcea E, Steinberg SM, Dahut W, Pluda J, Kruger EA, Reed E, Figg WD. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001; 24: 1050–1057.
- 102 Nakayama EE, Ura S, Fleury RN, Soares V. Renal lesions in leprosy: a retrospective study of 199 autopsies. Am J Kidney Dis 2001; 38: 26–30.
- 103 Nations SP, Katz JS, Lyde CB, Barohn RJ. Leprous neuropathy: an American perspective. Semin Neurol 1998; 18: 113–124.
- 104 Ng V, Zanazzi G, Timpl R, Talts JF, Salzer JL, Brennan PJ, Rambukkana A. Role of the cell wall phenolic glycolipid-1 in the peripheral nerve predilection of Mycobacterium leprae. Cell 2000; 103: 511–524.
- 105No authors listed. Randomized controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi. Lancet 1996; 348: 17–24.
- 106 Noordeen SK. Prophylaxis—scope and limitations. Lepr Rev 2000; 71(Suppl): S16–S19.
- 107 Noordeen SK, Lopez Bravo L, Sundaresan TK. Estimated number of leprosy cases in the world. Ind J Lepr 1992; 64: 521–527.
- 108 Ochoa MT, Stenger S, Sieling PA, Thoma-Uszynski S, Sabet S, Cho S, Krensky AM, Rollinghoff M, Nunes Sarno E, Burdick AE, Rea TH, Modlin RL. T-cell release of granulysin contributes to host defense in leprosy. Nat Med 2001; 7: 174–179.
- 109 Ooi WW, Moschella SL. Update on leprosy in immigrants in the United States: status in the year 2000. Clin Infect Dis 2001; 32: 930–937.
- 110 Pearson JM, Vedagiri M. Treatment of moderately severe erythema nodosum leprosum with thalidomide—a double-blind controlled trial. Lepr Rev 1969; 40: 111–116.
- 111 Pedley JC, Harman DJ, Waudby H, McDougall AC. Leprosy in peripheral nerves: histopathological findings in 119 untreated patients in Nepal. J Neurol Neurosurg Psychiatry 1980; 43: 198–204.
- 112 Pereira JH, Palande DD, Gschmeissner SE. Mycobacteria in nerve trunks of long-term treated leprosy patients. Lepr Rev 1991; 62: 134–142.
- 113 Ramadan W, Mourad B, Fadel W, Ghoraba E. Clinical, electrophysiological, and immunopathological study of peripheral nerves in Hansen's disease. Lepr Rev 2001; 72: 35–49.
- 114 Rambukkana A, Yamada H, Zanazzi G, Mathus T, Salzer JL, Yurchenco PD, Campbell KP, Fischetti VA. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 1998; 282: 2076–2079.
- 115 Rambukkana A, Zanazzi G, Tapinos N, Salzer JL. Contact-dependent demyelination by Mycobacterium leprae in the absence of immune cells. Science 2002; 296: 927–931
- 116 Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255–273.
- 117 Ridley DS, Job CK. The pathology of leprosy. In: RC Hastings, editor. Leprosy. New York: Churchill Livingstone; 1985. p 129.
- 118 Roger M, Levee G, Chanteau S, Gicquel B, Schurr E. No evidence for linkage between leprosy susceptibility and the human natural resistance-associated macrophage protein 1 (NRAMP1) gene in French Polynesia. Int J Lepr Other Mycobact Dis 1997; 65: 197–202.
- 119 Roche PW, Britton WJ, Failbus SS, Ludwig H, Theuvenet WJ, Adiga RB. Heterogeneity of serological responses in paucibacillary leprosy—differential responses to protein and carbohydrate antigens and correlation with clinical parameters. Int J Lepr Other Mycobact Dis 1990; 58: 319–327.
- 120 Roche PW, Britton WJ, Failbus SS, Theuvenet WJ, Lavender M, Adiga RB. Serological responses in primary neuritic leprosy. Trans R Soc Trop Med Hyg 1991; 85: 299–302.
- 121 Sabin TD, Swift TR, Jacobson RR. Leprosy. In: PJ Dyck, PK Thomas, editors. Peripheral neuropathy. Philadelphia: WB Saunders; 1993. p 1354–1379.
- 122 Sabin TD, Swift TR. Neurological complications of leprosy. In: MJ Aminoff, editor. Neurology and general medicine, 3rd ed. Philadelphia: Churchill Livingstone; 2001. p 709–718.
- 123 Sadoh DR, Hawk JL, Panayiotopoulos CP. F-chronodispersion in patients on thalidomide. Clin Neurophysiol 1999; 110: 735–739.
- 124 Saha K, Agarwal SK. Immune deficit in patients with lepromatous leprosy: its nature and relation to genetic factors, spectrum, and duration of the illness. Int J Lepr Other Mycobact Dis 1979; 47: 1–6.
- 125 Salgame P, Abrams JS, Clayberger C, Goldstein H, Convit J, Modlin RL, Bloom BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science 1991; 254: 279–282.
- 126 Samant G, Shetty VP, Uplekar MW, Antia NH. Clinical and electrophysiological evaluation of nerve function impairment following cessation of multidrug therapy in leprosy. Lepr Rev 1999; 70: 10–20.
- 127 Sampaio EP, Hernandez MO, Carvalho DS, Sarno EN. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed Pharmacother 2002; 56: 13–19.
- 128 Sampaio EP, Kaplan G, Miranda A, Nery JA, Miguel CP, Viana SM, Sarno EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408–414.
- 129 Sarno EN, Grau GE, Vieira LM, Nery JA. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states. Clin Exp Immunol 1991; 84: 103–108.
- 130 Saunderson P. The epidemiology of reactions and nerve damage. Lepr Rev 2000; 71(Suppl): S106–S110.
- 131 Saunderson P, Gebre S, Byass P. ENL reactions in the multibacillary cases of the AMFES cohort in central Ethiopia: incidence and risk factors. Lepr Rev 2000; 71: 318–324.
- 132 Saunderson P, Gebre S, Byass, P. Reversal Reactions in the skin lesions of AMFES patients: incidence and risk factors. Lepr Rev 2000; 71: 309–317.
- 133 Saunderson P, Gebre S, Desta K, Byass P, Lockwood DN. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000; 71: 285–308.
- 134 Schlesinger LS, Horwitz MA. Phenolic glycolipid-1 of Mycobacterium leprae binds complement component C3 in serum and mediates phagocytosis by human monocytes. J Exp Med 1991; 174: 1031–1038.
- 135 Scollard DM. Association of Mycobacterium leprae with human endothelial cells in vitro. Lab Invest 2000; 80: 663–669.
- 136 Scollard DM, Gillis TP, Williams DL. Polymerase chain reaction assay for the detection and identification of Mycobacterium leprae in patients in the United States. Am J Clin Pathol 1998; 109: 642–646.
- 137 Scollard DM, McCormick G, Allen JL. Localization of mycobacterium leprae to endothelial cells of epineurial and perineurila blood vessels and lymphatics. Am J Pathol 1999; 154: 1611–1620.
- 138 Selmaj KW, Raine CS. TNF mediates myelin and oligodendrocytes damage in vitro. Ann Neurol 1988; 23: 339–346.
- 139 Sengupta U. Immunopathology of leprosy: a state of the art. Int J Lepr Other Mycobact Dis 2001; 69(Suppl): S36–S41.
- 140 Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B. Presence of M. leprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 1999; 70: 281–286.
- 141 Shaw MA, Donaldson IJ, Collins A, Peacock CS, Lins-Lainson Z, Shaw JJ, Ramos F, Silveira F, Blackwell JM. Association and linkage of leprosy phenotypes with HLA class II and tumour necrosis factor genes. Genes Immunol 2001; 2: 196–204.
- 142 Shepard CC. The nasal excretion of Mycobacterium leprae in leprosy. Int J Lepr 1962; 30: 10–18.
- 143 Shepard CC, Guinto RS. Immunological identification of foot-pad isolates as mycobacterium leprae by lepromin reactivity in leprosy patients. J Exp Med 1963; 118: 195–204.
- 144 Sheskin J, Convit J. Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis 1969; 37: 135–146.
- 145 Shetty VP, Uplekar MW, Antia NH. Immunohistological localization of mycobacterial antigens within the peripheral nerves of treated leprosy patients and their significance to nerve damage in leprosy. Acta Neuropathol (Berl) 1994; 88: 300–306.
- 146 Shetty VP, Wakade A, Antia NH. A high incidence of viable Mycobacterium leprae in post-MDT recurrent lesions in tuberculoid leprosy patients. Lepr Rev 2001; 72: 337–344.
- 147 Shuttleworth JS, Ross H. Secondary amyloidosis in leprosy. Ann Intern Med 1956; 45: 23–38.
- 148 Singh G, Tutakne MA, Tiwari VD, Dutta RK. Inoculation leprosy developing after tattooing—a case report. Indian J Lepr 1985; 57: 887–888.
- 149 Sirsat AM, Lalitha VS, Pandya SS. Dapsone neuropathy—report of three cases and pathologic features of a motor nerve. Int J Lepr Other Mycobact Dis 1987; 55: 23–29.
- 150 Smith WC. Review of current research in the prevention of nerve damage in leprosy. Lepr Rev 2000; 71(Suppl): S138–S144.
- 151 Spierings E, de Boer T, Wieles B, Adams LB, Marani E, Ottenhoff TH. Mycobacterium leprae-specific, HLA class II-restricted killing of human Schwann cells by CD4+ Th1 cells: a novel immunopathogenic mechanism of nerve damage in leprosy. J Immunol 2001; 166: 5883–5888.
- 152 Spierings E, De Boer T, Zulianello L, Ottenhoff TH. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol 2000; 78: 349–355.
- 153 Suneetha S, Arunthathi S, Kurian N, Chacko CJ. Histological changes in the nerve, skin and nasal mucosa of patients with primary neuritic leprosy. Acta Leprol 2000; 12: 11–18.
- 154 Swift TR, Hackett ER, Shipley DE, Miner KM. The peroneal and tibial nerves in lepromatous leprosy. Clinical and electrophysiologic observations. Int J Lepr Other Mycobact Dis 1973; 41: 25–34.
- 155 Thacker AK, Chandra S, Mukhija RD, Sarkari NB. Electro-physiological evaluation of nerves during reactions in leprosy. J Neurol 1996; 243: 530–535.
- 156 Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, Akira S, Norgard MV, Belisle JT, Godowski PJ, Bloom BR, Modlin RL. Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 2001; 291: 1544–1547.
- 157 Torres P, Camarena JJ, Gomez JR, Nogueira JM, Gimeno V, Navarro JC, Olmos A. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts. Lepr Rev 2003; 74: 18–30.
- 158 Turkof E, Richard B, Assadian O, Khatri B, Knolle E, Lucas S. Leprosy affects facial nerves in a scattered distribution from the main trunk to all peripheral branches and neurolysis improves muscle function of the face. Am J Trop Med Hyg 2003; 68: 81–88.
- 159 Ulvi H, Yoldas T, Yigiter R, Mungen B. R–R interval variation and the sympathetic skin response in the assessment of the autonomic nervous system in leprosy patients. Acta Neurol Scand 2003; 107: 42–49.
- 160 Uplekar MW, Antia NH. Clinical and histopathological observations on pure neuritic leprosy. Ind J Lepr 1986; 58: 513–521.
- 161 Uyemura K, Dixon JF, Wong L, Rea TH, Modlin RL. Effect of cyclosporine A in erythema nodosum leprosum. J Immunol 1986; 137: 3620–3623.
- 162 Van Brakel WH. Prophylactic steroids to prevent nerve function impairment in leprosy: the effect of pre-existing neuropathy observed in the TRIPOD trial. Sixteenth International Leprosy Congress, 2002.
- 163 Van Brakel WH. Peripheral neuropathy in leprosy and its consequences. Lepr Rev 2000; 71(Suppl): S146–S153.
- 164 van Brakel WH, Khawas IB. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev 1994; 65: 350–360.
- 165 Verghese M, Ittimani KV, Satyanarayan KR, Mathai R, Bhakthaviziam C. A study of the conduction velocity of the motor fibers of ulnar and median nerves in leprosy. Int J Lepr Other Mycobact Dis 1970; 38: 271–277.
- 166 Weddell GM, Pearson JM. Leprosy—histopathologic aspects of nerve involvement. Contemp Neurol Ser 1975; 12: 17–28.
- 167 Weng XM, Chen SY, Ran SP, Zhang CH, Li HY. Immuno-histopathology in the diagnosis of early leprosy. Int J Lepr Other Mycobact Dis 2000; 68: 426–433.
- 168 Wilder-Smith EP, Wilder-Smith AJ, Nirkko AC. Skin and muscle vasomotor reflexes in detecting autonomic dysfunction in leprosy. Muscle Nerve 2000; 23: 1105–1112.
- 169 Yamamura M, Uyemura K, Deans RJ, Weinberg K, Rea TH, Bloom BR, Modlin RL. Defining protective responses to pathogens: cytokine profiles in leprosy lesions. Science 1991; 254: 277–279.
- 170 Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, Modlin RL. Cytokine patterns of immunologically mediated tissue damage. J Immunol 1992; 149: 1470–1475.
- 171 Yoder LJ, Guerra I. Hansen's disease. A guide to management in the United States. Carville, LA: National Hansen's Disease Programs; 1996.